| Literature DB >> 19816563 |
Sabine Pereyre1, Pascal Sirand-Pugnet, Laure Beven, Alain Charron, Hélène Renaudin, Aurélien Barré, Philippe Avenaud, Daniel Jacob, Arnaud Couloux, Valérie Barbe, Antoine de Daruvar, Alain Blanchard, Cécile Bébéar.
Abstract
Mycoplasma hominis is an opportunistic human mycoplasma. Two other pathogenic human species, M. genitalium and Ureaplasma parvum, reside within the same natural niche as M. hominis: the urogenital tract. These three species have overlapping, but distinct, pathogenic roles. They have minimal genomes and, thus, reduced metabolic capabilities characterized by distinct energy-generating pathways. Analysis of the M. hominis PG21 genome sequence revealed that it is the second smallest genome among self-replicating free living organisms (665,445 bp, 537 coding sequences (CDSs)). Five clusters of genes were predicted to have undergone horizontal gene transfer (HGT) between M. hominis and the phylogenetically distant U. parvum species. We reconstructed M. hominis metabolic pathways from the predicted genes, with particular emphasis on energy-generating pathways. The Embden-Meyerhoff-Parnas pathway was incomplete, with a single enzyme absent. We identified the three proteins constituting the arginine dihydrolase pathway. This pathway was found essential to promote growth in vivo. The predicted presence of dimethylarginine dimethylaminohydrolase suggested that arginine catabolism is more complex than initially described. This enzyme may have been acquired by HGT from non-mollicute bacteria. Comparison of the three minimal mollicute genomes showed that 247 CDSs were common to all three genomes, whereas 220 CDSs were specific to M. hominis, 172 CDSs were specific to M. genitalium, and 280 CDSs were specific to U. parvum. Within these species-specific genes, two major sets of genes could be identified: one including genes involved in various energy-generating pathways, depending on the energy source used (glucose, urea, or arginine) and another involved in cytadherence and virulence. Therefore, a minimal mycoplasma cell, not including cytadherence and virulence-related genes, could be envisaged containing a core genome (247 genes), plus a set of genes required for providing energy. For M. hominis, this set would include 247+9 genes, resulting in a theoretical minimal genome of 256 genes.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19816563 PMCID: PMC2751442 DOI: 10.1371/journal.pgen.1000677
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Comparison of general features of the M. hominis genome with those of M. genitalium G37 (ATCC 33530) and U. parvum serovar 3 (ATCC 700970).
| Features |
|
|
|
| Genome size (bp) |
| 580,074 | 751,719 |
| GC content of genome (%) |
| 31.7 | 25.5 |
| Gene density (%) |
| 91.2 | 91.3 |
| Total number of CDS |
| 482 | 614 |
| Hypothetical proteins |
| 2 | 182 |
| Conserved hypothetical proteins |
| 164 | 107 |
| CDSs with predicted fonction |
| 316 | 325 |
| Pseudogenes |
| 5 | 0 |
| Average protein length (aa) |
| 363 | 371 |
| Proteins with predicted MW>300 kDa |
| 0 | 2 |
| Predicted lipoproteins |
| 18 | 37 |
| rRNA sets |
| 1 | 2 |
| tRNA |
| 36 | 30 |
| Start codon usage (%) | |||
| AUG |
| 88.5 | 92.5 |
| UUG |
| 4.1 | 3.0 |
| GUG |
| 7.4 | 4.5 |
| Other |
| 0 | 0 |
| Stop codon usage (%) | |||
| UAA |
| 72 | 85 |
| UAG |
| 27 | 14 |
| Tryptophan codon usage (%) | |||
| UGA |
| 64 | 87 |
| UGG |
| 36 | 13 |
Previously published data [3],[11], not including average protein length, the high molecular weight protein prediction, and start and stop codon usage, obtained from the MolliGen website (http://cbi.labri.fr/outils/molligen).
Each part of a pseudogene is counted.
Data from the Integrated Microbial Genomes website (http://imgweb.jgi-psf.org/cgi-bin/w/main.cgi?page=home).
Lipoprotein number based on genome annotation.
Two sets of 16S–23S rRNA genes and two single 5S rRNA genes elsewhere in the genome.
CDS, coding sequence; ND, not determined; MW, molecular weight.
Horizontal transfer candidates.
|
| Closest homolog | |||||
| Mnemonic | Predicted function | Accession number or mnemonic | Species | % Similarity | Highest similarity in Hominis group % | Comment |
|
| Aminopeptidase C | O69192 |
| 59 | no | contains motif COG3579, PepC, aminopeptidase C |
|
| Diadenosine 5′5′″-P1,P4-tetraphosphatepyrophosphohydrolase (MutT/nudix family protein) | EDP68279 |
| 66 | no | no homolog in mycoplasmas |
|
| Conserved hypothetical protein | Q48SX1 |
| 66 | no | homologs in several firmicutes from the microbiota |
|
| N-dimethylarginine dimethylaminohydrolase | ZP_03894500 |
| 76 | no | predicted N-dimethylarginine dimethylaminohydrolase in |
|
| Virulence-associated protein D | O05728 |
| 60 | no | contains motif VapD, uncharacterized virulence-associated protein D, no homolog in mycoplasmas |
|
| Cytosine-specific DNA-methyltransferase/Type II site-specific deoxyribonuclease | MSC0216 |
| 83 | 47 | Highly related orthologs in |
|
| Type III restriction enzyme | UU476 |
| 71 | 57 | |
|
| Pseudogene of Type III restriction-modification system: methylase (part 2) | UU477 |
| 57 | 76 | probable phase variation, split in |
|
| Pseudogene of Type III restriction-modification system: methylase (part 1) | UU478 |
| 76 | 73 | probable phase variation, split in |
|
| Pseudogene of transposase for insertion sequence element IS1138, (part 1) | UU374 |
| 95 | no | truncated |
|
| Pseudogene of transposase for insertion sequence element IS1138, (part 2) | UU372 |
| 94 | 66 | truncated |
|
| Truncated integrase-recombinase protein | UU372 |
| 96 | 67 | truncated |
|
| ATP synthase beta chain | UU054 |
| 92 | 86 | |
|
| ATP synthase alpha chain | UU053 |
| 86 | 80 | |
|
| Conserved hypothetical protein | UU052 |
| 69 | 46 | 3 TMB |
|
| Conserved hypothetical protein | UU051 |
| 68 | 57 | |
|
| Conserved hypothetical protein | UU050 |
| 82 | 69 | |
|
| Conserved hypothetical protein | UU049 |
| 69 | 61 | |
|
| Conserved hypothetical protein | UU048 |
| 72 | 51 | 12 TMB predicted |
|
| Conserved hypothetical protein | UU046 |
| 72 | 63 | 1 TMB predicted |
|
| Conserved hypothetical protein, predicted lipoprotein | UU045 |
| 65 | 54 | predicted lipoprotein |
|
| Type I restriction enzyme specificity protein | UU096 |
| 56 | 46 | split in |
|
| Type I restriction enzyme specificity protein | UU099 |
| 45 | 43 | truncated in |
|
| Pseudogene of Type I restriction enzyme M protein (C-terminal part) | UU098 |
| 81 | 77 | split in |
|
| Pseudogene of Type I restriction enzyme M protein (N-terminal part) | UU098 |
| 75 | 81 | split in |
|
| Type I restriction enzyme M protein | UU098 |
| 74 | 80 | split in |
|
| Type I restriction enzyme specificity protein | UU096 |
| 62 | 46 | split in |
|
| Type I restriction enzyme specificity protein | UU099 |
| 89 | 50 | truncated in |
|
| Type I restriction-modification system endonuclease | UU095 |
| 65 | 70 | inferred by synteny |
Except in the phylogenetically closest related M. arthritidis.
TMB, transmembrane segment.
Figure 1Comparative analysis of the genomes of three minimal mollicutes affecting humans.
(A) Number of specific and shared CDSs for the genomes of M. hominis PG21, M. genitalium G37, and U. parvum serovar 3. (B) Focus on known species-specific proteins involved in cytadherence/virulence and energy-generating pathways. LMP, large membrane protein; PTS, phosphoenolpyruvate phosphotransferase system; HGT, horizontal gene transfer; UP, U. parvum; MH, M. hominis; MG, M. genitalium.
Figure 2Comparison of carbohydrate- and arginine-metabolism pathways and transporters encoded by M. hominis PG21, M. genitalium G37, and U. parvum serovar 3.
Metabolic products are shown in black. Putative proteins present in M. hominis are shown in green; proteins absent from M. hominis are shown in red. “MG” in purple boxes indicates that the gene encoding the corresponding protein is present in the M. genitalium G37 genome. “UP” in blue boxes means that the gene encoding the corresponding protein is present in the U. parvum genome. Transporters are colored according to their substrates: yellow, cations; green, anions and amino-acids; orange, carbohydrates; purple, multidrug and metabolic end product efflux. Arrows indicate the direction of substrate transport.
Growth of M. hominis PG21 in the presence of arginine and arginine analogs.
|
| Growth in CCU/ml | ||
| t = 0 | t = 48 h | t = 120 h | |
| No supplement | 105 (7.0) | 107 (7.2) | 106 (7.4) |
| Arginine (10 mM) | 105 (7.0) | 107 (8.1) | 0 (8.2) |
| No supplement + Arginine (23 mM) at t = 48 h | 105 (7.0) | 107 (7.2) | 105 (7.9) |
| Canavanine (10 mM) | 105 (7.0) | 105 (6.7) | 105 (6.8) |
| Canavanine (10 mM) at t = 0 + arginine (23 mM) at t = 48 h | 105 (7.0) | 105 (6.7) | 107 (7.2) |
| Canavanine (10 mM) +ADMA | 105 (7.0) | 105 (6.9) | ND |
containing heart infusion broth, yeast extract and 2.5% horse serum.
CCU/ml, color changing unit/ml.
ADMA, N,N-dimethyl-L-arginine.
ND: not determined.